“…Potential risks associated with specific HPCs may include immunogenicity, adjuvant activity, proteolytic activity, and direct biological activity of potent molecules (e.g., cytokines); examples of all of these are documented in the literature. [1][2][3][4][5] Currently, immunoassays are almost universally used to monitor total residual HCP levels in the industry (the use of Fourier transform mid infrared spectroscopy has also recently been reported 6 ), but whether specific, critical HCPs should be individually measured is an open question. 7,8 Monoclonal antibodies (mAbs) constitute a substantial portion of the biopharmaceutical industry's current biotherapeutics portfolio, and downstream purification of mAbs has evolved into platform processes that are highly similar across the pharmaceutical industry.…”